Psychosocial and Public Health Impacts of New HIV Therapies

1. Front Matter

   Pages i-xix

   PDF

2. Combination Antiretroviral Chemotherapy

   • Kenneth H. Mayer

   Pages 1-31

3. Pharmacokinetics of Protease Inhibitors and Drug Interactions with Psychoactive Drugs

   • Susan K. Chuck, Keith A. Rodvold, Lisa L. Von Moltke, David J. Greenblatt, Richard I. Shader

   Pages 33-60

4. Treatment Adherence to HIV Medications

   • Judith Godwin Rabkin, Margaret Chesney

   Pages 61-82

5. Combination Antiretroviral Therapies for HIV

   • Steven D. Pinkerton, David R. Holtgrave

   Pages 83-112

6. Ethical Issues in the Use of New Treatments for HIV

   • Elizabeth Heitman, Michael W. Ross

   Pages 113-135

7. Mental Health Implications of New HIV Treatments

   • Seth C. Kalichman, Bineetha Ramachandran

   Pages 137-150

8. Practical Prevention Issues

   • David G. Ostrow

   Pages 151-169

9. Postexposure Prophylaxis

   • Mike Shriver

   Pages 171-182

10. Behavioral Research Needs and Challenges of New Treatments

    • Willo Pequegnat, Ellen Stover

    Pages 183-194

11. Back Matter

    Pages 195-218

    PDF

“AIDS is kind of like life, just speeded up. ” JavonP. ,heroinaddictwithAIDS, Bronx,NewYork, 1988 “Now I’m not so much scared of dying as scared of living. ” Mike D. , heroin addict with AIDS, New Haven, Connecticut, 1998 Within little more than a decade, AIDS has been tranformed from an untreatable, rapidly fatal illness, into a manageable, chronic disease. Most of this tranformation has occurred in the past five years, accelerated by the advent of protease inhibitors and the proven benefits of combination antiretroviral therapy and prophylaxis against opportunistic infections. For people living with HIV/AIDS, these developments have offered unprecedented hope, and also new challenges. As reflected in the quotes above, some of the anxieties and anticipation of premature dying have been replaced by the uncertainties involved in living with a long-term, unpredictable illness. The role of caregivers for people with HIV/AIDS has also changed radically over this time. Earlier in the epidemic, we learned to accompany patients through illness, to bear witness, to advocate, to address issues of death, dying, and - reavement. The arrival of more effective therapy has brought with it new capabi- ties, but also new complexities, raising difficult problems concerning access to care, adherence, and toxicity.

• AIDS
• HIV
• HIV/AIDS
• Public Health
• prevention
• infectious diseases

• Howard Brown Health Center and University of Illinois/Chicago School of Public Health, Chicago

  David G. Ostrow

• Center for AIDS Intervention Research (CAIR), Medical College of Wisconsin, Milwaukee

  Seth C. Kalichman

Policies and ethics